Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665067 · ClinicalTrials.gov registry record
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 592
- Enrollment target
NCT00665067: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT00665067 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 592 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00665067 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 592 participants
- Enrollment target
Study Summary
Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone marrow. The results of these studies will be correlated with subjects' disease symptoms and response to their experimental treatment. The MPD-RC researchers are interested in studying molecules from the blood and bone marrow, the exact molecules changing over time with the investigators choosing only the most promising for investigation. The investigators are attempting to better understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is believed that further basic knowledge about these cancer cells as well as the effects of treatment will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. The MPD-RC is hoping to determine if a number of laboratory tests (biomarkers) will allow for the prediction of response in future patients to the treatment they would receive.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 592 participants |
| Start Date | 2007-04 |
| Est. Completion | 2018-07-20 |
What the finished NCT00665067 record still lists
NCT00665067 is an observational study that tracks outcomes without assigning an intervention. The registered 592 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00665067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00665067 about?
NCT00665067 is a clinical study titled "Correlative Biomarker Study in Patients With Myeloproliferative Disorders". Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone ...
What is the current status of trial NCT00665067?
This trial is currently completed. The enrollment target is 592 participants. The study started on 2007-04. Estimated completion is 2018-07-20.
Who is sponsoring clinical trial NCT00665067?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia